{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:06:40Z","timestamp":1794661600712,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12955-018-0930-y","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T07:35:06Z","timestamp":1526888106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Grammati","family":"Sarri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menaka","family":"Bhor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seye","family":"Abogunrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Nandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Halloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Revicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"930_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033\u201348.","journal-title":"JAMA"},{"key":"930_CR2","first-page":"895","volume":"72","author":"ER Meier","year":"2012","unstructured":"Meier ER, Miller JL. Sickle cell disease in children. Drugs. 2012;72:895\u2013906.","journal-title":"Drugs"},{"key":"930_CR3","first-page":"449","volume-title":"Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease: A Biopsychosocial Approach","author":"J Schatz","year":"2006","unstructured":"Schatz J, Puffer ES. Neuropsychological aspects of sickle cell disease. In: Brown RT, editor. Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease: A Biopsychosocial Approach. New York: Oxford University Press; 2006. p. 449\u201370."},{"key":"930_CR4","unstructured":"Evidence-based management of sickle cell disease: Expert panel report. \n                    https:\/\/www.nhlbi.nih.gov\/health-topics\/evidence-based-management-sickle-cell-disease\n                    \n                  . Accessed 14 May 2018."},{"key":"930_CR5","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","volume":"361","author":"MM Hsieh","year":"2009","unstructured":"Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361:2309\u201317.","journal-title":"N Engl J Med"},{"key":"930_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","volume":"18","author":"NR Kamani","year":"2012","unstructured":"Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the blood and marrow transplant clinical trials network (BMT CTN). Biology of Blood and Marrow Transplantation. 2012;18:1265\u201372.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"930_CR7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood-2013-03-489112","volume":"122","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, Bernaudin F, Vermylen C, Dalle J-H, Stein J. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122:1072\u20138.","journal-title":"Blood"},{"key":"930_CR8","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","volume":"377","author":"WC Wang","year":"2011","unstructured":"Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663\u201372.","journal-title":"Lancet"},{"key":"930_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317\u201322.","journal-title":"N Engl J Med"},{"key":"930_CR10","unstructured":"The Voice of the Patient. A series of reports from the U.S. Food and Drug Administration's (FDA's) Patient-focused Drug Development Initiative. Sickle Cell Disease. \n                    https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM418430.pdf\n                    \n                  . Accessed 14 May 2018."},{"key":"930_CR11","doi-asserted-by":"publisher","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. \n                    https:\/\/doi.org\/10.1186\/2046-4053-4-1\n                    \n                  .","DOI":"10.1186\/2046-4053-4-1"},{"key":"930_CR12","unstructured":"Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. Available from \n                    http:\/\/handbook.cochrane.org\n                    \n                  ."},{"key":"930_CR13","unstructured":"How to develop a search strategy for a Cochrane Review. \n                    http:\/\/training.cochrane.org\/handbook\n                    \n                  . Accessed 14 May 2018."},{"key":"930_CR14","unstructured":"The COSMIN checklist. \n                    http:\/\/www.cosmin.nl\/cosmin_checklist.html\n                    \n                  . Accessed 14 May 2018."},{"key":"930_CR15","unstructured":"Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. \n                    http:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf\n                    \n                  . Accessed 14 May 2018."},{"key":"930_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-4-1","volume":"4","author":"US Department of Health, Evaluation HSFCfD, research, US Department of Health, evaluation HSFCfB, research, US Department of Health, human services FDA Center for devices, radiological health","year":"2006","unstructured":"US Department of Health, Evaluation HSFCfD, research, US Department of Health, evaluation HSFCfB, research, US Department of Health, human services FDA Center for devices, radiological health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:1\u201320.","journal-title":"Health Qual Life Outcomes"},{"key":"930_CR17","first-page":"116","volume":"14","author":"M Cooper-Effa","year":"2001","unstructured":"Cooper-Effa M, Blount W, Kaslow N, Rothenberg R, Eckman J. Role of spirituality in patients with sickle cell disease. J Am Board Fam Pract. 2001;14:116\u201322.","journal-title":"J Am Board Fam Pract"},{"key":"930_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0005-7967(99)00140-0","volume":"38","author":"R Edwards","year":"2000","unstructured":"Edwards R, Telfair J, Cecil H, Lenoci J. Reliability and validity of a self-efficacy instrument specific to sickle cell disease. Behav Res Ther. 2000;38:951\u201363.","journal-title":"Behav Res Ther"},{"key":"930_CR19","doi-asserted-by":"publisher","first-page":"e4528","DOI":"10.1097\/MD.0000000000004528","volume":"95","author":"CT Evensen","year":"2016","unstructured":"Evensen CT, Treadwell MJ, Keller S, Levine R, Hassell KL, Werner EM, Smith WR. Quality of care in sickle cell disease: cross-sectional study and development of a measure for adults reporting on ambulatory and emergency department care. Medicine. 2016;95:e4528.","journal-title":"Medicine"},{"key":"930_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/01612840.2012.656823","volume":"33","author":"C Jenerette","year":"2012","unstructured":"Jenerette C, Brewer CA, Crandell J, Ataga KI. Preliminary validity and reliability of the sickle cell disease health-related stigma scale. Issues in mental health nursing. 2012;33:363\u20139.","journal-title":"Issues in mental health nursing"},{"key":"930_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/1043659609360712","volume":"21","author":"C Jenerette","year":"2010","unstructured":"Jenerette C, Dixon J. Developing a short form of the simple Rathus assertiveness schedule using a sample of adults with sickle cell disease. J Transcult Nurs. 2010;21:314\u201324.","journal-title":"J Transcult Nurs"},{"key":"930_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/1074840710385000","volume":"16","author":"CM Jenerette","year":"2010","unstructured":"Jenerette CM, Valrie CR. The influence of maternal behaviors during childhood on self-efficacy in individuals with sickle cell disease. J Fam Nurs. 2010;16:422\u201334.","journal-title":"J Fam Nurs"},{"key":"930_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/NCN.0b013e3181d7820b","volume":"28","author":"A Jha","year":"2010","unstructured":"Jha A, Suarez ML, Ferrans CE, Molokie R, Kim YO, Wilkie DJ. Cognitive testing of PAINReportIt\u00ae in adult African Americans with sickle cell disease. Computers, informatics, nursing: CIN. 2010;28:141.","journal-title":"Computers, informatics, nursing: CIN"},{"key":"930_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12955-014-0125-0","volume":"12","author":"SD Keller","year":"2014","unstructured":"Keller SD, Yang M, Treadwell MJ, Werner EM, Hassell KL. Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-me item banks. Health Qual Life Outcomes. 2014;12:125.","journal-title":"Health Qual Life Outcomes"},{"key":"930_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/MPH.0000000000000110","volume":"36","author":"A Sobota","year":"2014","unstructured":"Sobota A, Akinlonu A, Champigny M, Eldridge M, McMahon L, Telfair J, Sprinz P. Self-reported transition readiness among young adults with sickle cell disease. J Pediatr Hematol Oncol. 2014;36:389.","journal-title":"J Pediatr Hematol Oncol"},{"key":"930_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jpain.2013.03.007","volume":"14","author":"WT Zempsky","year":"2013","unstructured":"Zempsky WT, O'Hara EA, Santanelli JP, Palermo TM, New T, Smith-Whitley K, Casella JF. Validation of the sickle cell disease pain burden interview\u2013youth. J Pain. 2013;14:975\u201382.","journal-title":"J Pain"},{"key":"930_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/09297040600770746","volume":"13","author":"OJ Clay","year":"2007","unstructured":"Clay OJ, Telfair J. Evaluation of a disease-specific self-efficacy instrument in adolescents with sickle cell disease and its relationship to adjustment. Child Neuropsychology. 2007;13:188\u2013203.","journal-title":"Child Neuropsychology"},{"key":"930_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/pbc.22497","volume":"55","author":"C Dampier","year":"2010","unstructured":"Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W. Health-related quality of life in children with sickle cell disease: a report from the comprehensive sickle cell centers clinical trial consortium. Pediatr Blood Cancer. 2010;55:485\u201394.","journal-title":"Pediatr Blood Cancer"},{"key":"930_CR29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/pbc.25944","volume":"63","author":"C Dampier","year":"2016","unstructured":"Dampier C, Barry V, Gross HE, Lui Y, Thornburg CD, DeWalt DA, Reeve BB. Initial evaluation of the pediatric PROMIS\u00ae health domains in children and adolescents with sickle cell disease. Pediatr Blood Cancer. 2016;63:1031\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"930_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00002508-199706000-00005","volume":"13","author":"KM Gil","year":"1997","unstructured":"Gil KM, Wilson JJ, Edens JL. The stability of pain coping strategies in young children, adolescents, and adults with sickle cell disease over an 18-month period. Clin J Pain. 1997;13:110\u20135.","journal-title":"Clin J Pain"},{"key":"930_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40271-016-0166-z","volume":"9","author":"N Gupta","year":"2016","unstructured":"Gupta N, Naegeli AN, Turner-Bowker DM, Flood EM, Heath LE, Mays SM, Dampier C. Cognitive testing of an electronic version of the faces pain scale-revised with pediatric and adolescent sickle cell patients. The Patient-Patient-Centered Outcomes Research. 2016;9:433\u201343.","journal-title":"The Patient-Patient-Centered Outcomes Research"},{"key":"930_CR32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/jpepsy\/jss087","volume":"37","author":"CW Karlson","year":"2012","unstructured":"Karlson CW, Leist-Haynes S, Smith M, Faith MA, Elkin TD, Megason G. Examination of risk and resiliency in a pediatric sickle cell disease population using the psychosocial assessment tool 2.0. J Pediatr Psychol. 2012;37:1031\u201340.","journal-title":"J Pediatr Psychol"},{"key":"930_CR33","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/jpepsy\/jsn036","volume":"33","author":"CB McClellan","year":"2008","unstructured":"McClellan CB, Schatz J, Sanchez C, Roberts CW. Validity of the pediatric quality of life inventory for youth with sickle cell disease. J Pediatr Psychol. 2008;33:1153\u201362.","journal-title":"J Pediatr Psychol"},{"key":"930_CR34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/MPH.0b013e31817e4a44","volume":"30","author":"JA Panepinto","year":"2008","unstructured":"Panepinto JA, Pajewski NM, Foerster LM, Hoffmann RG. The performance of the PedsQL\u2122 generic Core scales in children with sickle cell disease. J Pediatr Hematol Oncol. 2008;30:666.","journal-title":"J Pediatr Hematol Oncol"},{"key":"930_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/pbc.24776","volume":"61","author":"JA Panepinto","year":"2014","unstructured":"Panepinto JA, Torres S, Bendo CB, McCavit TL, Dinu B, Sherman-Bien S, Bemrich-Stolz C, Varni JW. PedsQL\u2122 multidimensional fatigue scale in sickle cell disease: feasibility, reliability, and validity. Pediatr Blood Cancer. 2014;61:171\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"930_CR36","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/pbc.24491","volume":"60","author":"JA Panepinto","year":"2013","unstructured":"Panepinto JA, Torres S, Bendo CB, McCavit TL, Dinu B, Sherman-Bien S, Bemrich-Stolz C, Varni JW. PedsQL\u2122 sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer. 2013;60:1338\u201344.","journal-title":"Pediatr Blood Cancer"},{"key":"930_CR37","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jpain.2014.09.008","volume":"15","author":"WT Zempsky","year":"2014","unstructured":"Zempsky WT, O'Hara EA, Santanelli JP, New T, Smith-Whitley K, Casella J, Palermo TM. Development and validation of the youth acute pain functional ability questionnaire (YAPFAQ). J Pain. 2014;15:1319\u201327.","journal-title":"J Pain"},{"key":"930_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.18553\/jmcp.2017.23.2.125","volume":"23","author":"AP Brogan","year":"2017","unstructured":"Brogan AP, DeMuro C, Barrett AM, D\u2019Alessio D, Bal V, Hogue SL. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. Journal of Managed Care & Specialty Pharmacy. 2017;23:125\u201334.","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"930_CR39","first-page":"264","volume":"6","author":"E Zagadailov","year":"2013","unstructured":"Zagadailov E, Fine M, Shields A. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. American health & drug benefits. 2013;6:264.","journal-title":"American health & drug benefits"},{"key":"930_CR40","unstructured":"Clinical Outcome Assessment Qualification Program [\n                    https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/ucm284077.htm\n                    \n                  . Accessed 14 May 2018."},{"key":"930_CR41","doi-asserted-by":"publisher","first-page":"c2921","DOI":"10.1136\/bmj.c2921","volume":"340","author":"J Speight","year":"2010","unstructured":"Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ. 2010;340:c2921.","journal-title":"BMJ"},{"key":"930_CR42","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","volume":"10","author":"DL Patrick","year":"2007","unstructured":"Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, O'neill R, Kennedy DL. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125\u201337.","journal-title":"Value Health"},{"key":"930_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11136-014-0765-x","volume":"24","author":"A Regnault","year":"2015","unstructured":"Regnault A, Hamel J-F, Patrick DL. Pooling of cross-cultural PRO data in multinational clinical trials: how much can poor measurement affect statistical power? Qual Life Res. 2015;24:273\u20137.","journal-title":"Qual Life Res"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-018-0930-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12955-018-0930-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-018-0930-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T19:10:39Z","timestamp":1558379439000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-018-0930-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["930"],"URL":"https:\/\/doi.org\/10.1186\/s12955-018-0930-y","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"27 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"MB, SN, and RH are employed by Novartis. GS, SA, and DR are employed by Evidera, which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations, and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Evidera received funding from Novartis to participate in the study and the development of this manuscript. CF was an employee of Evidera at the time the review was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"99"}}